ES2702246T3 - Formulaciones de agente de unión IgG4 estables - Google Patents

Formulaciones de agente de unión IgG4 estables Download PDF

Info

Publication number: ES2702246T3
Authority: ES; Spain
Prior art keywords: antibody; formulation; cxcr5; light; amino acid
Prior art date: 2012-03-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES13714505T

Other languages

English (en)

Spanish (es)

Inventor

Dirk Usener

Ahmed Youssef

Annika Hagendorf

Martina Kirsch

Sabrina Ruggeberg

Julia Schnieders

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi SA

Original Assignee

Sanofi SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-26

Filing date

2013-03-26

Publication date

2019-02-28

2013-03-26 Application filed by Sanofi SA filed Critical Sanofi SA

2013-03-26 Priority claimed from PCT/US2013/033881 external-priority patent/WO2013148686A2/en

2019-02-28 Application granted granted Critical

2019-02-28 Publication of ES2702246T3 publication Critical patent/ES2702246T3/es

Status Active legal-status Critical Current

2033-03-26 Anticipated expiration legal-status Critical

Links

239000000203 mixture Substances 0.000 title claims abstract description 464
238000009472 formulation Methods 0.000 title claims abstract description 450
239000011230 binding agent Substances 0.000 title description 92
101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims abstract description 224
102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims abstract description 223
125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 149
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract description 96
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 90
239000000872 buffer Substances 0.000 claims abstract description 83
238000003860 storage Methods 0.000 claims abstract description 38
239000003795 chemical substances by application Substances 0.000 claims abstract description 37
102000009410 Chemokine receptor Human genes 0.000 claims abstract description 9
108050000299 Chemokine receptor Proteins 0.000 claims abstract description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 115
150000001413 amino acids Chemical class 0.000 claims description 65
108090000623 proteins and genes Proteins 0.000 claims description 65
102000004169 proteins and genes Human genes 0.000 claims description 65
239000007979 citrate buffer Substances 0.000 claims description 61
229930006000 Sucrose Natural products 0.000 claims description 60
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 60
239000005720 sucrose Substances 0.000 claims description 60
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 59
239000002953 phosphate buffered saline Substances 0.000 claims description 59
239000011780 sodium chloride Substances 0.000 claims description 57
239000004475 Arginine Substances 0.000 claims description 50
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 50
239000000178 monomer Substances 0.000 claims description 40
108010029485 Protein Isoforms Proteins 0.000 claims description 37
102000001708 Protein Isoforms Human genes 0.000 claims description 37
230000007935 neutral effect Effects 0.000 claims description 24
230000002378 acidificating effect Effects 0.000 claims description 21
239000007857 degradation product Substances 0.000 claims description 18
230000002829 reductive effect Effects 0.000 claims description 18
239000012929 tonicity agent Substances 0.000 claims description 17
239000006227 byproduct Substances 0.000 claims description 7
230000008707 rearrangement Effects 0.000 claims description 7
239000012669 liquid formulation Substances 0.000 claims description 5
239000003708 ampul Substances 0.000 claims description 4
229940090047 auto-injector Drugs 0.000 claims description 4
239000012931 lyophilized formulation Substances 0.000 claims description 3
229920001213 Polysorbate 20 Polymers 0.000 abstract description 37
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract description 37
229940068977 polysorbate 20 Drugs 0.000 abstract description 37
108090000765 processed proteins & peptides Proteins 0.000 description 94
102000004196 processed proteins & peptides Human genes 0.000 description 89
229920001184 polypeptide Polymers 0.000 description 85
239000000427 antigen Substances 0.000 description 84
108091007433 antigens Proteins 0.000 description 84
102000036639 antigens Human genes 0.000 description 84
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 77
229960002885 histidine Drugs 0.000 description 77
235000014304 histidine Nutrition 0.000 description 77
235000001014 amino acid Nutrition 0.000 description 76
239000000546 pharmaceutical excipient Substances 0.000 description 76
230000027455 binding Effects 0.000 description 71
230000035882 stress Effects 0.000 description 66
239000012634 fragment Substances 0.000 description 65
229940024606 amino acid Drugs 0.000 description 64
235000018102 proteins Nutrition 0.000 description 63
235000002639 sodium chloride Nutrition 0.000 description 58
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 53
238000000034 method Methods 0.000 description 53
125000000539 amino acid group Chemical group 0.000 description 51
230000001404 mediated effect Effects 0.000 description 51
229960003121 arginine Drugs 0.000 description 49
235000009697 arginine Nutrition 0.000 description 49
238000001542 size-exclusion chromatography Methods 0.000 description 49
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 46
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 45
201000010099 disease Diseases 0.000 description 45
239000000243 solution Substances 0.000 description 45
238000002296 dynamic light scattering Methods 0.000 description 44
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 42
108010047041 Complementarity Determining Regions Proteins 0.000 description 40
102100038968 WAP four-disulfide core domain protein 1 Human genes 0.000 description 40
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
239000004094 surface-active agent Substances 0.000 description 38
102000005962 receptors Human genes 0.000 description 34
108020003175 receptors Proteins 0.000 description 34
239000000126 substance Substances 0.000 description 31
238000003989 weak cation exchange chromatography Methods 0.000 description 31
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 30
210000004027 cell Anatomy 0.000 description 29
230000008646 thermal stress Effects 0.000 description 29
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 28
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 28
230000000694 effects Effects 0.000 description 28
239000000523 sample Substances 0.000 description 28
229940074410 trehalose Drugs 0.000 description 28
239000003446 ligand Substances 0.000 description 27
150000007523 nucleic acids Chemical group 0.000 description 27
238000004458 analytical method Methods 0.000 description 26
238000004519 manufacturing process Methods 0.000 description 26
238000001914 filtration Methods 0.000 description 25
230000014509 gene expression Effects 0.000 description 25
239000000463 material Substances 0.000 description 25
238000011282 treatment Methods 0.000 description 24
239000004471 Glycine Substances 0.000 description 23
239000000047 product Substances 0.000 description 23
102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 22
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 22
101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 22
229930195725 Mannitol Natural products 0.000 description 22
230000004071 biological effect Effects 0.000 description 22
239000000539 dimer Substances 0.000 description 22
239000000594 mannitol Substances 0.000 description 22
235000010355 mannitol Nutrition 0.000 description 22
108020004707 nucleic acids Proteins 0.000 description 22
102000039446 nucleic acids Human genes 0.000 description 22
239000008351 acetate buffer Substances 0.000 description 21
230000000144 pharmacologic effect Effects 0.000 description 21
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 description 20
108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 20
239000002253 acid Substances 0.000 description 20
230000015572 biosynthetic process Effects 0.000 description 20
230000001965 increasing effect Effects 0.000 description 19
229960003646 lysine Drugs 0.000 description 19
230000009467 reduction Effects 0.000 description 19
-1 such as an antibody Substances 0.000 description 19
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 18
239000004472 Lysine Substances 0.000 description 18
235000018977 lysine Nutrition 0.000 description 18
239000008186 active pharmaceutical agent Substances 0.000 description 17
238000000113 differential scanning calorimetry Methods 0.000 description 17
208000024891 symptom Diseases 0.000 description 17
238000012360 testing method Methods 0.000 description 17
238000002965 ELISA Methods 0.000 description 16
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 16
210000001744 T-lymphocyte Anatomy 0.000 description 16
230000002776 aggregation Effects 0.000 description 16
238000004220 aggregation Methods 0.000 description 16
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 15
108060003951 Immunoglobulin Proteins 0.000 description 15
210000003719 b-lymphocyte Anatomy 0.000 description 15
230000007423 decrease Effects 0.000 description 15
102000018358 immunoglobulin Human genes 0.000 description 15
230000000069 prophylactic effect Effects 0.000 description 15
239000003381 stabilizer Substances 0.000 description 15
238000011161 development Methods 0.000 description 14
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 13
230000004048 modification Effects 0.000 description 13
238000012986 modification Methods 0.000 description 13
238000002360 preparation method Methods 0.000 description 13
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 12
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 12
238000007792 addition Methods 0.000 description 12
239000012528 membrane Substances 0.000 description 12
239000002245 particle Substances 0.000 description 12
235000013930 proline Nutrition 0.000 description 12
238000012216 screening Methods 0.000 description 12
238000007920 subcutaneous administration Methods 0.000 description 12
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 11
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 11
208000022559 Inflammatory bowel disease Diseases 0.000 description 11
102000004083 Lymphotoxin-alpha Human genes 0.000 description 11
108090000542 Lymphotoxin-alpha Proteins 0.000 description 11
239000007853 buffer solution Substances 0.000 description 11
150000001720 carbohydrates Chemical group 0.000 description 11
239000003814 drug Substances 0.000 description 11
238000011049 filling Methods 0.000 description 11
230000001939 inductive effect Effects 0.000 description 11
238000001990 intravenous administration Methods 0.000 description 11
229920000136 polysorbate Polymers 0.000 description 11
238000002560 therapeutic procedure Methods 0.000 description 11
239000008215 water for injection Substances 0.000 description 11
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 10
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 10
238000013019 agitation Methods 0.000 description 10
239000005557 antagonist Substances 0.000 description 10
238000003556 assay Methods 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
206010039073 rheumatoid arthritis Diseases 0.000 description 10
238000011146 sterile filtration Methods 0.000 description 10
238000003756 stirring Methods 0.000 description 10
208000009329 Graft vs Host Disease Diseases 0.000 description 9
101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 9
238000004422 calculation algorithm Methods 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
239000000499 gel Substances 0.000 description 9
239000011521 glass Substances 0.000 description 9
208000024908 graft versus host disease Diseases 0.000 description 9
230000002401 inhibitory effect Effects 0.000 description 9
239000007788 liquid Substances 0.000 description 9
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 9
229950008882 polysorbate Drugs 0.000 description 9
230000028327 secretion Effects 0.000 description 9
238000006467 substitution reaction Methods 0.000 description 9
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 8
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 8
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 8
230000000903 blocking effect Effects 0.000 description 8
230000001413 cellular effect Effects 0.000 description 8
208000035475 disorder Diseases 0.000 description 8
230000002163 immunogen Effects 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
238000005259 measurement Methods 0.000 description 8
125000003729 nucleotide group Chemical group 0.000 description 8
239000008363 phosphate buffer Substances 0.000 description 8
229940124597 therapeutic agent Drugs 0.000 description 8
102100036848 C-C motif chemokine 20 Human genes 0.000 description 7
102100032367 C-C motif chemokine 5 Human genes 0.000 description 7
108010055166 Chemokine CCL5 Proteins 0.000 description 7
101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 7
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
239000008366 buffered solution Substances 0.000 description 7
230000015556 catabolic process Effects 0.000 description 7
238000006731 degradation reaction Methods 0.000 description 7
238000012217 deletion Methods 0.000 description 7
230000037430 deletion Effects 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
238000007710 freezing Methods 0.000 description 7
230000006870 function Effects 0.000 description 7
230000028993 immune response Effects 0.000 description 7
230000006872 improvement Effects 0.000 description 7
230000003993 interaction Effects 0.000 description 7
230000007774 longterm Effects 0.000 description 7
239000002773 nucleotide Substances 0.000 description 7
235000019333 sodium laurylsulphate Nutrition 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 6
208000011231 Crohn disease Diseases 0.000 description 6
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 6
229960003589 arginine hydrochloride Drugs 0.000 description 6
230000008859 change Effects 0.000 description 6
230000001684 chronic effect Effects 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
238000010790 dilution Methods 0.000 description 6
239000012895 dilution Substances 0.000 description 6
238000009826 distribution Methods 0.000 description 6
230000008014 freezing Effects 0.000 description 6
230000001900 immune effect Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000001155 isoelectric focusing Methods 0.000 description 6
238000005457 optimization Methods 0.000 description 6
230000001954 sterilising effect Effects 0.000 description 6
239000012906 subvisible particle Substances 0.000 description 6
206010009900 Colitis ulcerative Diseases 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
201000006704 Ulcerative Colitis Diseases 0.000 description 5
230000001594 aberrant effect Effects 0.000 description 5
235000019445 benzyl alcohol Nutrition 0.000 description 5
239000006172 buffering agent Substances 0.000 description 5
238000012512 characterization method Methods 0.000 description 5
210000004602 germ cell Anatomy 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
208000028774 intestinal disease Diseases 0.000 description 5
238000007726 management method Methods 0.000 description 5
238000010369 molecular cloning Methods 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
229920001983 poloxamer Polymers 0.000 description 5
239000008389 polyethoxylated castor oil Substances 0.000 description 5
239000011148 porous material Substances 0.000 description 5
230000002265 prevention Effects 0.000 description 5
241000894007 species Species 0.000 description 5
238000004659 sterilization and disinfection Methods 0.000 description 5
235000000346 sugar Nutrition 0.000 description 5
235000002374 tyrosine Nutrition 0.000 description 5
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
239000012905 visible particle Substances 0.000 description 5
DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
101000830594 Homo sapiens Tumor necrosis factor ligand superfamily member 14 Proteins 0.000 description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
108010076504 Protein Sorting Signals Proteins 0.000 description 4
229920001304 Solutol HS 15 Polymers 0.000 description 4
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
239000004473 Threonine Substances 0.000 description 4
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
230000004913 activation Effects 0.000 description 4
235000003704 aspartic acid Nutrition 0.000 description 4
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
239000012707 chemical precursor Substances 0.000 description 4
239000003638 chemical reducing agent Substances 0.000 description 4
238000001035 drying Methods 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
230000036541 health Effects 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
229960000310 isoleucine Drugs 0.000 description 4
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
235000014705 isoleucine Nutrition 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
238000002703 mutagenesis Methods 0.000 description 4
231100000350 mutagenesis Toxicity 0.000 description 4
230000003204 osmotic effect Effects 0.000 description 4
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
235000008729 phenylalanine Nutrition 0.000 description 4
210000002381 plasma Anatomy 0.000 description 4
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
229940068968 polysorbate 80 Drugs 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
238000002741 site-directed mutagenesis Methods 0.000 description 4
229960000999 sodium citrate dihydrate Drugs 0.000 description 4
229910001220 stainless steel Inorganic materials 0.000 description 4
239000010935 stainless steel Substances 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
235000008521 threonine Nutrition 0.000 description 4
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical group [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 4
239000004474 valine Substances 0.000 description 4
235000014393 valine Nutrition 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
108091023037 Aptamer Proteins 0.000 description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 3
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
239000004695 Polyether sulfone Substances 0.000 description 3
239000004743 Polypropylene Substances 0.000 description 3
241000700159 Rattus Species 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
108020004459 Small interfering RNA Proteins 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
230000004075 alteration Effects 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
239000003435 antirheumatic agent Substances 0.000 description 3
229920005557 bromobutyl Polymers 0.000 description 3
230000005754 cellular signaling Effects 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
239000012459 cleaning agent Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000005520 cutting process Methods 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
230000006240 deamidation Effects 0.000 description 3
239000002988 disease modifying antirheumatic drug Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
229920002313 fluoropolymer Polymers 0.000 description 3
239000004811 fluoropolymer Substances 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
235000013922 glutamic acid Nutrition 0.000 description 3
239000004220 glutamic acid Substances 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
235000004554 glutamine Nutrition 0.000 description 3
102000051198 human TNFSF14 Human genes 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
235000006109 methionine Nutrition 0.000 description 3
229920006393 polyether sulfone Polymers 0.000 description 3
229920001155 polypropylene Polymers 0.000 description 3
239000012602 primary packaging material Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
235000004400 serine Nutrition 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
229940083575 sodium dodecyl sulfate Drugs 0.000 description 3
239000008362 succinate buffer Substances 0.000 description 3
JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 3
230000009261 transgenic effect Effects 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
102000019352 CXC chemokine receptor 5 Human genes 0.000 description 2
108010061298 CXCR5 Receptors Proteins 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
208000009386 Experimental Arthritis Diseases 0.000 description 2
108010008177 Fd immunoglobulins Proteins 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108700005091 Immunoglobulin Genes Proteins 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
238000012369 In process control Methods 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
241000288906 Primates Species 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
239000012505 Superdex™ Substances 0.000 description 2
VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
238000011374 additional therapy Methods 0.000 description 2
230000004520 agglutination Effects 0.000 description 2
230000009435 amidation Effects 0.000 description 2
238000007112 amidation reaction Methods 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
229960004106 citric acid Drugs 0.000 description 2
238000004140 cleaning Methods 0.000 description 2
238000004590 computer program Methods 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
210000004544 dc2 Anatomy 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000001212 derivatisation Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000012502 diagnostic product Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
239000012636 effector Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000013020 final formulation Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
229960002449 glycine Drugs 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
102000049118 human CXCR5 Human genes 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000036512 infertility Effects 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
238000004190 ion pair chromatography Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
238000002356 laser light scattering Methods 0.000 description 2
235000005772 leucine Nutrition 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000004807 localization Effects 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
239000008176 lyophilized powder Substances 0.000 description 2
238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
210000003519 mature b lymphocyte Anatomy 0.000 description 2
239000002609 medium Substances 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
238000011169 microbiological contamination Methods 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
238000001139 pH measurement Methods 0.000 description 2
239000011236 particulate material Substances 0.000 description 2
230000006320 pegylation Effects 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
229940068965 polysorbates Drugs 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
229940071643 prefilled syringe Drugs 0.000 description 2
238000011045 prefiltration Methods 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
239000012460 protein solution Substances 0.000 description 2
230000006337 proteolytic cleavage Effects 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
229960004641 rituximab Drugs 0.000 description 2
238000005070 sampling Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000010257 thawing Methods 0.000 description 2
229940074409 trehalose dihydrate Drugs 0.000 description 2
239000011123 type I (borosilicate glass) Substances 0.000 description 2
239000012904 visual particle Substances 0.000 description 2
238000012784 weak cation exchange Methods 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 description 1
108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
101710082516 C-X-C chemokine receptor type 5 Proteins 0.000 description 1
108091008928 CXC chemokine receptors Proteins 0.000 description 1
102000054900 CXCR Receptors Human genes 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
239000004395 L-leucine Substances 0.000 description 1
229940099968 LIGHT antagonist Drugs 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
229920001219 Polysorbate 40 Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
229920002642 Polysorbate 65 Polymers 0.000 description 1
239000004614 Process Aid Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
108700012920 TNF Proteins 0.000 description 1
108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 description 1
102000012883 Tumor Necrosis Factor Ligand Superfamily Member 14 Human genes 0.000 description 1
102100024586 Tumor necrosis factor ligand superfamily member 14 Human genes 0.000 description 1
230000010530 Virus Neutralization Effects 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000012491 analyte Substances 0.000 description 1
238000001286 analytical centrifugation Methods 0.000 description 1
239000000538 analytical sample Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000003286 arthritogenic effect Effects 0.000 description 1
238000012865 aseptic processing Methods 0.000 description 1
239000010426 asphalt Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
230000001914 calming effect Effects 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
230000005889 cellular cytotoxicity Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
239000002577 cryoprotective agent Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
229940119744 dextran 40 Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002270 exclusion chromatography Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000005429 filling process Methods 0.000 description 1
238000002189 fluorescence spectrum Methods 0.000 description 1
230000003325 follicular Effects 0.000 description 1
210000000285 follicular dendritic cell Anatomy 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000013022 formulation composition Substances 0.000 description 1
238000012395 formulation development Methods 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002337 glycosamines Chemical group 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
230000001788 irregular Effects 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000011147 magnesium chloride Nutrition 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229960005027 natalizumab Drugs 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
210000001986 peyer's patch Anatomy 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
150000003022 phthalic acids Chemical class 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229960005141 piperazine Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229940101027 polysorbate 40 Drugs 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
229940099511 polysorbate 65 Drugs 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
238000004313 potentiometry Methods 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000004886 process control Methods 0.000 description 1
230000004845 protein aggregation Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000010926 purge Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
238000009517 secondary packaging Methods 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000010008 shearing Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
NPJMDBHUQHLEPR-FHNDMYTFSA-M sodium;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;chloride Chemical compound [Na+].[Cl-].OC(=O)[C@@H](N)CCCN=C(N)N NPJMDBHUQHLEPR-FHNDMYTFSA-M 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000013112 stability test Methods 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
125000000185 sucrose group Chemical group 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
238000009120 supportive therapy Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
229910021642 ultra pure water Inorganic materials 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
239000012498 ultrapure water Substances 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
239000002699 waste material Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

ES13714505T 2012-03-26 2013-03-26 Formulaciones de agente de unión IgG4 estables Active ES2702246T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261615539P	2012-03-26	2012-03-26
FR1351013		2013-02-06
PCT/US2013/033881 WO2013148686A2 (en)	2012-03-26	2013-03-26	Stable igg4 binding agent formulations

Publications (1)

Publication Number	Publication Date
ES2702246T3 true ES2702246T3 (es)	2019-02-28

Family

ID=54834982

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES13714505T Active ES2702246T3 (es)	2012-03-26	2013-03-26	Formulaciones de agente de unión IgG4 estables

Country Status (4)

Country	Link
JP (1)	JP6820823B2 (pt)
ES (1)	ES2702246T3 (pt)
HK (1)	HK1204990A1 (pt)
PT (1)	PT2830658T (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040033228A1 (en) *	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
UA94264C2 (ru) *	2006-04-21	2011-04-26	Новартис Аг	Стабильная жидкая фармацевтическая композиция, которая содержит антагонистическое моноклональное антитело к cd40
MX2009002151A (es) *	2006-08-28	2009-07-03	Kirin Pharma Kk	Anticuerpos monoclonales humanos especificos para light humano antagonistas.
CA2682170A1 (en) *	2007-03-30	2008-10-09	Medimmune, Llc	Antibodies with decreased deamidation profiles
FI20075278A0 (fi) *	2007-04-20	2007-04-20	Biotie Therapies Corp	Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
US8647622B2 (en) *	2007-08-29	2014-02-11	Sanofi	Humanized anti-CXCR5 antibodies, derivatives thereof and their use
FR2942799B1 (fr) *	2009-03-06	2011-02-25	Lfb Biotechnologies	Anticorps monoclonal anti-rhesus d
JO3417B1 (ar) *	2010-01-08	2019-10-20	Regeneron Pharma	الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CN105055306B (zh) *	2010-05-28	2019-10-01	诺沃—诺迪斯克有限公司	包含抗体和防腐剂的稳定的多剂量组合物

2013
- 2013-03-26 PT PT13714505T patent/PT2830658T/pt unknown
- 2013-03-26 ES ES13714505T patent/ES2702246T3/es active Active
2015
- 2015-06-22 HK HK15105917.2A patent/HK1204990A1/xx unknown
2017
- 2017-10-25 JP JP2017205914A patent/JP6820823B2/ja active Active

Also Published As

Publication number	Publication date
PT2830658T (pt)	2018-12-28
JP6820823B2 (ja)	2021-01-27
HK1204990A1 (en)	2015-12-11
JP2018048174A (ja)	2018-03-29

Publication	Publication Date	Title
US10525130B2 (en)	2020-01-07	Stable IGG4 based binding agent formulations
ES2827180T3 (es)	2021-05-20	Formulaciones de anticuerpos estables
US10689451B2 (en)	2020-06-23	Anti-BAFFR antibody therapeutic formulations
CN104736175B (zh)	2019-11-01	抗催乳素受体抗体制剂
BR112014023952B1 (pt)	2023-01-24	Formulações de agentes de ligação à base de igg4 estáveis, kit, e dispositivo ou recipiente pré-cheios
ES2818229T3 (es)	2021-04-09	Formulación anti-IFNAR1 estable
KR102624564B1 (ko)	2024-01-12	항-ctla4 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-ctla4 항체의 안정한 제제 및 그의 사용 방법
ES2925992T3 (es)	2022-10-20	Formulaciones estables de polipéptidos
ES2732243T3 (es)	2019-11-21	Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
KR102594028B1 (ko)	2023-10-24	항-pd-1 항체 조성물
US20110256135A1 (en)	2011-10-20	Anti-nerve growth factor (ngf) antibody compositions
BR112019022698A2 (pt)	2020-05-19	formulações estáveis de anticorpos anti-tigit isolados e em combinação com anticorpos do receptor de morte programada 1 (pd-1) e métodos de uso das mesmas
ES2860480T3 (es)	2021-10-05	Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos
US20220111048A1 (en)	2022-04-14	Antibody formulations
US12139533B2 (en)	2024-11-12	Liquid formulations of anti-CD200 antibodies
ES2702246T3 (es)	2019-02-28	Formulaciones de agente de unión IgG4 estables
KR20230026407A (ko)	2023-02-24	액티빈 a 항체 제형 및 이의 사용 방법
KR20240038005A (ko)	2024-03-22	B7-h3 항체의 약학적 조성물 및 그것의 용도